The invention discloses application of irisin in the preparation of drugs for preventing myocardial ischemia reperfusion injuries. Experimental results show that irisin can decrease the myocardial infarction area caused by ischemia reperfusion, reduce the increase of the contents of lactate dehydrogenase (LDH), troponin (cTnI), creatine kinase (CK), and other myocardial enzyme markers caused by ischemia reperfusion, meanwhile reducing the inflammatory response, myocardial apoptosis, and oxidative stress response caused by myocardial ischemia reperfusion, promote peroxysome proliferator-activated receptor .gamma. nuclear translocation, and inhibit nuclear transcription factor NF-.kappa.B nuclear translocation and accordingly decrease myocardial structure injuries and load increase caused by ischemia reperfusion. Therefore, irisin can be used for preventing and decreasing myocardial reperfusion injuries and has important clinical significance on the treatment of myocardial ischemia.

THIRD AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL UNIVERSITY

Application of irisin in myocardial ischemia reperfusion

A skin model comprises keratinocytes capable of overexpressing filaggrin. A method for evaluating the in vitro activity of a formulation or of at least one active agent on the healing of nipple skin and/or on the reduction of nipple skin inflammation, by bringing said active agent or said formulation into contact with a skin model comprising keratinocytes overexpressing filaggrin and also comprising a lesion, and measuring the level of production of at least one biological marker chosen from lactate dehydrogenase (LDH), TNF.alpha., filaggrin, TGF.beta.1 and .beta.1 integrin.

lactate dehydrogenase/põletik

Application of irisin in myocardial ischemia reperfusion

Reconstituted nipple skin model

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus